检索结果-南通市图书馆

Frontiers of Medicine 2021年第2期15卷 208-220页

作者： Wenjie Zhu binghe xu National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciencesand Peking Union Medical CollegeBeijing 100021China

New targeted therapies have been developed to overcome resistance to endocrine therapy(ET)and improve the outcome of HR^(+)/HER2^(-)advanced breast cancer(ABC).We conducted a meta-analysis and systemic review on randomized controlled trials evaluating various targeted therapies in combination with ET in HR^(+)/HER2^(-)*** and EMBASE databases were searched for eligible *** ratios(HRs)for progression-free survival(PFS),odds ratios(ORs)for objective response rate(ORR),clinical benefit rate(CBR),and toxicity were ***-six studies with data on 10347 patients were included and *** addition of cyclin-dependent kinase 4/6 inhibitors to ET significantly improved median PFS(pooled HR=0.547,P<0.001),overall survival(pooled HR=0.755,P<0.001),and tumor response rates(ORR,pooled OR=1.478,P<0.001;CBR,pooled OR=1.201,P<0.001)with manageable toxicities(pooled OR=3.280,P<0.001).The mammalian targets of rapamycin inhibitors and exemestane were not clinically beneficial for this pooled population including ET-naïve and ET-resistant *** improvement in PFS(pooled HR=0.686,P<0.001)yet pronounced toxicities(pooled OR=2.154,P<0.001)were noted in the combination of phosphatidylinositol-4,5-bisphosphate 3-kinase inhibitors with *** studies are warranted to optimize the population and the dosing sequence of these available options.

关键词： endocrine-resistant HR^(+)/HER2^(-)advanced breast cancer randomized clinical trials meta-analysis targeted therapy

Targeted therapeutic options and future perspectives for HER2-positive breast cancer

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2019年第1期4卷 347-368页

作者： Jiani Wang binghe xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeNo.17PanjiayuannanliChaoyang District100021 BeijingChina State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeNo.17PanjiayuannanliChaoyang District100021 BeijingChina

Over the past 2 decades,there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2(HER2)-positive breast ***,pertuzumab,lapatinib,and ado-trastuzumab emtansine(T-DM1)are commonly recommended anti-HER2 target agents by the *** and Drug *** review summarizes the most significant and updated research on clinical scenarios related to HER2-positive breast cancer management in order to revise the guidelines of everyday clinical *** this article,we present the data on anti-HER2 clinical research of neoadjuvant,adjuvant,and metastatic studies from the past 2 *** also highlight some of the promising strategies that should be critically ***,this review lists some of the ongoing clinical trials,findings of which may soon be available.

关键词： breast HER2 clinical

Progress in systemic therapy for triple-negative breast cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Frontiers of Medicine 2021年第1期15卷 1-10页

作者： Hongnan Mo binghe xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Triple-negative breast cancer(TNBC)is the most aggressive subtype of breast cancer with a heterogeneous genetic *** exhibits substantial activity in a small subset of these *** resistance is *** progress has been made in the genetic analysis of TNBC to identify novel targets and increase the precision of therapeutic *** progress has translated into major advances in treatment strategies,including modified chemotherapy approaches,immune checkpoint inhibitors,and targeted therapeutic *** of these strategies have been evaluated in clinical ***,patient selection remains a considerable challenge in clinical practice.

关键词： triple-negative breast cancer immunotherapy targeted therapy

Breast cancer: Epidemiology, risk factors and screening

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2023年第6期35卷 565-583页

作者： Hangcheng xu binghe xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Breast cancer is a global health concern with a significant impact on the well-being of women. Worldwide, the past several decades have witnessed changes in the incidence and mortality of breast cancer. Additionally,epidemiological data reveal distinct geographic and demographic disparities globally. A range of modifiable and non-modifiable risk factors are established as being associated with an increased risk of developing breast *** review discusses genetic, hormonal, behavioral, environmental, and breast-related risk factors. Screening plays a critical role in the effective management of breast cancer. Various screening modalities, including mammography,ultrasound, magnetic resonance imaging(MRI), and physical examination, have different applications, and a combination of these modalities is applied in practice. Current screening recommendations are based on factors including age and risk, with a significant emphasis on minimizing potential harms to achieve an optimal benefits-to-harms ratio. This review provides a comprehensive insight into the epidemiology, risk factors, and screening of breast cancer. Understanding these elements is crucial for improving breast cancer management and reducing its burden on affected individuals and healthcare systems.

关键词： Breast neoplasms epidemiology mass screening risk factors

Preface to Special Issue: Cancer epidemiology, risk factors and screening

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2023年第6期35卷 563-564页

作者： binghe xu Hangcheng xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Cancer continues to be one of the leading causes of morbidity and mortality worldwide, posing significant challenges to public health systems. The International Agency for Research on Cancer(IARC) revealed an increase... 详细信息

关键词： Cancer epidemiology mortality

Breast cancer:an up-to-date review and future perspectives

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2022年第10期42卷 913-936页

作者： Ruoxi Hong binghe xu Department of Medical Oncology Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdong 510060P.R.China State Key Laboratory of Molecular Oncology and Department of Medical Oncology Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100006P.R.China

Breast cancer is the most common cancer *** occurrence of breast cancer is associated with many risk factors,including genetic and hereditary pre*** cancers are highly *** strategies for breast cancer vary by molecular features,including activation of human epidermal growth factor receptor 2(HER2),hormonal receptors(estrogen receptor[ER]and progesterone receptor[PR]),gene mutations(e.g.,mutations of breast cancer 1/2[BRCA1/2]and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha[PIK3CA])and markers of the immune microenvironment(e.g.,tumor-infiltrating lymphocyte[TIL]and programmed death-ligand 1[PDL1]).Early-stage breast cancer is considered curable,for which local-regional therapies(surgery and radiotherapy)are the cornerstone,with systemic therapy given before or after surgery when *** or neoadjuvant therapy,including targeted drugs or immune checkpoint inhibitors,has become the standard of care for most early-stage HER2-positive and triple-negative breast cancer,followed by risk-adapted post-surgical *** ER-positive early breast cancer,endocrine therapy for 5-10 years is *** breast cancer with distant metastases is currently considered *** therapies in this setting include endocrine therapy with targeted agents,such as CDK4/6 inhibitors and phosphoinositide 3-kinase(PI3K)inhibitors for hormone receptor-positive disease,anti-HER2 targeted therapy for HER2-positive disease,poly(ADP-ribose)polymerase inhibitors for BRCA1/2 mutation carriers and immunotherapy currently for part of triple-negative *** technologies of precision medicine may guide individualized treatment escalation or de-escalation in the *** this review,we summarized the latest scientific information and discussed the future perspectives on breast cancer.

关键词： PIK3CA Breast cancer

Guidelines for diagnosis and treatment of advanced breast cancer in China(2022 edition)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of the National Cancer Center

Journal of the National Cancer Center 2024年第2期4卷 107-127页

作者：无 binghe xu Fei Ma Breast Cancer Expert Committee of National Quality Control Center for Cancer Breast Cancer Expert Committee of China Anti-Cancer Association Cancer Drug Clinical Research Committee of China Anti-Cancer Association Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijingChina

Breast cancer is the most common cancer among women *** has been estimated that about 416000 new cases and over 117000 deaths of breast cancer occurred in China in *** the new cases of breast cancer diagnosed each year,3-10%have distant metastasis at the time of initial *** addition,approxi-mately 30%of patients with early-stage breast cancer may eventually experience recurrence or *** 5-year survival rate of patients with advanced breast cancer is only 20%with a median overall survival of 2-3 *** advanced breast cancer remains incurable at present,new therapeutic options and multidisci-plinary treatment could be utilized to alleviate symptoms,improve quality of life,and prolong patients’*** choice of treatment regimens for patients with advanced breast cancer is very important,and the optimal treatment strategy beyond the first-and second-line therapy is often ***,the China Advanced Breast Cancer Guideline Panel discussed and summarized recent clinical evidence,updated the guidelines for the diag-nosis and treatment of advanced breast cancer based on the 2020 edition,and formulated the“Guidelines for diagnosis and treatment of advanced breast cancer in China(2022 edition)”for clinicians’reference.

关键词： Breast neoplasms Diagnosis Treatment Guideline

Neuroendocrine carcinoma of the breast:a review of 126 cases in China

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2017年第9期36卷 444-447页

作者： Yiqun Li Feng Du Wenjie Zhu binghe xu Department of Medical Oncology National Cancer Centre/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China

Neuroendocrine carcinoma of the breast (NECB) accounts for approximately 0.3%-0.5% of all breast cancers [1, 2]. Due to the rarity of NECB, current understanding of this disease in China is limited to case reports and small case series, and large data analysis is still lacking. Therefore, we conducted the most comprehensive literature search to date, aiming to analyze the clinicopathologic characteristics as well as treatment and outcome of NECB in the Chinese population.

关键词： NECB Chinese population

Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2017年第5期29卷 411-418页

作者： Jiani Wang Qing Li binghe xu Tongtong Zhang Shanshan Chen Yang Luo Department of Medical Oncology National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College

Objective： Chemotherapy with paclitaxel is associated with significant neurotoxicity that may offset patients＇ quality of life and therapeutic benefits. This prospective, non-randomized control study evaluated the efficacy and safety of an antidepressant drug, duloxetine, at 30 or 60 mg/d, in the treatment of paclitaxel-induced peripheral neuropathy（PIPN） in Chinese breast cancer ***：A total of 102 patients with a median age of 50（range,25–60）years,treated in the Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,between November 2014 and January 2017 were finally *** by baseline characteristics,the patients were classified into two groups,receiving either duloxetine or alternative antineurotoxicity *** the course of the paclitaxel regimen,the eligibility criteria included sensory neuropathy,as evaluated by the National Cancer Institute-Common Toxicity Criteria for Adverse *** treatment consisted of receiving 30 mg duloxetine（for the first 4 weeks）and 60 mg duloxetine for an additional 8 weeks,or any other anti-neurotoxicity drug daily during the same crossover *** improvement associated with PIPN from the patient’s perspective were assessed by the Functional Assessment of Cancer Therapy-Taxane（FACT-Tax）Scales,which contained questions scored from 0 to 4（0,not at all;4,very much;total score range,0–44）.Results：Duloxetine was more effective in decreasing PIPN（odds ratio=5.426;95%confidence interval,1.898–15.514;P=0.002）.Between duloxetine group and control group,the median（25th–75th percentiles）decreasing difference in the FACT-Tax pain score was 4（2–6）vs.1（0–4）（P=0.005）.Conclusions：Duloxetine is a promising and safe option with tolerable toxicity at a dose of 60 mg/d for Chinese breast cancer patients with ***-neuropathy adverse events were mild and similar in both *** major toxicities of duloxetine included nausea,c

关键词： Duloxetine FACT-Tax Scales paclitaxel peripheral neuropathy

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart(TQB2450)and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第12期8卷 5944-5953页

作者： Yiqun Han Jiayu Wang Tao Sun Quchang Ouyang Jianwen Li Jie Yuan binghe xu National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Liaoning Cancer Hospital&Institute ShenyangLiaoning 110042China Hunan Cancer Hospital ChangshaHunan 410013China Geneplus-Shenzhen Shenzhen 518118China

In our phase Ib trial(*** Identifier:NCT03855358),benmelstobart(TQB2450),a novel humanized IgG1 antibody against PD-L1,plus antiangiogenic multikinase inhibitor,anlotinib,demonstrated promising antitumor activities in pretreated triple negative breast cancer(TNBC)*** conducted explorative analyses of genomic biomarkers to explore the associations with treatment response and survival *** next generation sequencing(NGS)was undertaken toward circulating tumor DNA(ctDNA)collected from peripheral blood samples prior to the start of treatment and after disease progression.A total of 31 patients received targeted NGS and functional driver mutations in 29 patients were *** most frequent mutations were TP53(72%),MLL3(28%),and PIK3CA(17%).At a blood-based tumor mutational burden(bTMB)cutoff of 6.7 mutations per megabase,patients with low bTMB showed better response to anlotinib plus TQB2450(50%vs.7%,P=0.015)and gained greater PFS benefits(7.3 vs.4.1 months,P=0.012)than those with high *** a maximum somatic allele frequency(MSAF)cutoff of 10%,a low MSAF indicated a better objective response(43%vs.20%)as well as a significantly longer median PFS(7.9 vs.2.7 months,P<0.001).Patients with both low MSAF and low bTMB showed a notably better objective response to anlotinib plus TQB2450(70%vs.11%,P<0.001)and a significantly longer median PFS(11.0 vs.2.9 months,P<0.001)than patients with other *** findings support future studes and validation of MSAF and the combined bTMB-MSAF classification as predictive biomarkers of immune checkpoint inhibitor-based regimens in advanced TNBC patients.

关键词： PIK3CA breast cancer